Clinical Trial Update: Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating daratumumab for relapsed/refractory B-cell or T-cell precursor acute lymphoblastic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Precursor Acute Lymphoblastic Leukemia
• T-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | Phase 2 | Status: WITHDRAWN